Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

value demonstration

The Vector Issue 3 banner

Access The Vector Issue 3: 15 payers describe the likely affect of EU General Pharmaceutical Legislation on orphan drug strategy

In the third issue of The Vector, Genesis Research asked 15 payers across France, Germany, Italy, Spain, and the UK how they believe the new EU General Pharmaceutical Legislation will...

Genesis Research Group

- PMLiVE

Alexion and Aide Health launch app for people with rare diseases

More than 3.5 million people in the UK live with a rare condition

- PMLiVE

Shionogi to acquire IntraBio in deal worth $2bn

The deal will expand Shionogi’s growing portfolio with IntraBio’s rare diseases capabilities

- PMLiVE

Ogsiveo recommended by NICE to treat rare soft tissue tumours

Desmoid tumours are rare soft tissue tumours that can grow aggressively into nearby tissues

- PMLiVE

J&J’s Darzalex combination treatment for untreated multiple myeloma recommended by NICE

Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer

- PMLiVE

LEO Pharma acquires rights for dersimelagon from Tanabe Pharma

The company will pay $435m in up front and near-term milestone payments

- PMLiVE

NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis

Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life

- PMLiVE

NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia

The treatments are for eligible adults in England and Wales

- PMLiVE

Ultomiris gets US FDA Priority Review for immunoglobulin A nephropathy treatment

If approved, this would be the first C5 complement inhibitor available for this rare kidney disease

- PMLiVE

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer

It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year

- PMLiVE

LEO Pharma to acquire Replay gene therapy platform

The acquisition will advance innovation for patients with rare skin diseases

- PMLiVE

Shionogi starts phase 2 clinical trial for Pompe Disease

The rare disease affects around one in every 22,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links